Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population
Clinical Lymphoma Myeloma and Leukemia · 2023
DOI: 10.1016/j.clml.2023.04.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2023. Verfasst von Amin Azem und 10 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Albany Medical Center, Albany, NY; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL. Electronic address: azema…. Hauptthemen laut MEDLINE: Lymphoma, Extranodal NK-T-Cell, Thrombocytopenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Moffitt Cancer Center.
Abstract (Originalsprache)
INTRODUCTION: L-asparaginase-based chemotherapy regimens are effective for treating chemotherapy-resistant natural killer- (NK-) cell neoplasms. To treat these lymphoma subtypes in Asia, where NK/T-cell lymphomas are more prevalent, the NK-Cell Tumor Study Group developed the SMILE regimen, which includes a steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide. In the US however, the only commercially available form of asparaginase is the pegylated form (PEG-asparaginase) which has been incorporated into a modified SMILE (mSMILE). We sought to study the toxicity associated with replacing L-asparaginase with PEG-asparaginase in mSMILE. PATIENTS AND METHODS: We retrospectively identified all adult patients treated with the mSMILE chemotherapy regimen in our database at Moffitt Cancer Center (MCC) between December 1, 2009, and July 30, 2021. Patients were included if they were treated with mSMILE irrespective of their underlying diagnosis. Toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5. The rate of toxicity in our mSMILE treatment group was numerically compared to data published in a metanalysis of the SMILE regimen's toxicity (Pokrovsky et al., 2019). RESULTS: A total of 21 patients were treated with mSMILE at MCC during the 12-year analysis window. Compared to patients receiving the L-asparaginase-based SMILE, patients receiving mSMILE experienced grade 3 or 4 leukopenia less often, with a toxicity rate of 62% (median with SMILE, 85% [95% CI, 74%-95%]); thrombocytopenia, however, was more common, with a toxicity rate of 57% (median with SMILE, 48% [95% CI, 40%-55%]). Other hematological, hepatic and coagulation related toxicities were also reported. CONCLUSION: In a non-Asian population, the mSMILE regimen with PEG-asparaginase is a safe alternative to the L-asparaginase-based SMILE regimen. There is a comparable risk of hematological toxicity, and no treatment-related mortality was seen in our population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine, Albany Medical Center, Albany, NY; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL. Electronic address: azema@amc.edu.
- Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Förderung
- Moffitt Cancer Center
Zitieren
APA
Azem, A., Caddell, R., Nelson, R., Isenalumhe, L., Gaballa, S., Chavez, J., Bello, C., Pinilla, J., Sokol, L., Shah, B., & Saeed, H. (2023). Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.04.005
Vancouver
Azem A, Caddell R, Nelson R, Isenalumhe L, Gaballa S, Chavez J, et al. Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population. Clinical Lymphoma Myeloma and Leukemia. 2023. doi:10.1016/j.clml.2023.04.005
BibTeX
@article{Azem2023,
author = {Azem, Amin and Caddell, Ryan and Nelson, Rebecca and Isenalumhe, Leidy and Gaballa, Sameh and Chavez, Julio and Bello, Celeste and Pinilla, Javier and Sokol, Lubomir and Shah, Bijal and Saeed, Hayder},
title = {Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2023},
doi = {10.1016/j.clml.2023.04.005}
}
EUVIMED